Skip to main content
PP

Pirouette Pharma

OnePush is a disc‑shaped, push‑button auto‑injector that automates needle insertion, drug delivery, and retraction while keeping the needle concealed throughout use. The API‑agnostic platform supports subcutaneous and intramuscular dosing for chronic injectable therapies, offering pharmaceutical partners a patient‑centric device that improves adherence and provides built‑in safety lockout and dose‑confirmation data capture.

Portsmouth, United StatesFounded 2017281K+ followers
Updated 3 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Patients requiring chronic injectable therapies often experience needle anxiety and find existing auto‑injectors cumbersome, leading to reduced initiation, lower adherence, and suboptimal health outcomes.

Solution

OnePush is a disc‑shaped, push‑button auto‑injector that fully automates needle insertion, delivery, and retraction while keeping the needle hidden throughout the process. The device’s controlled, smooth insertion motion minimizes needle sensation, enabling confident self‑administration at home. Its API‑agnostic architecture allows pharmaceutical partners to integrate both novel and established injectable APIs for subcutaneous or intramuscular dosing without reformulating the drug. By delivering a low‑friction, single‑step experience, OnePush improves patient preference, supports long‑term dosing schedules, and provides brands with a differentiated delivery platform that can drive higher compliance and persistency.

Target Audience

Pharmaceutical companies developing chronic injectable treatments—such as oncology, HIV, and other long‑term therapies—seeking a patient‑centric delivery device that enhances adherence and brand differentiation.

Features

  • Fully automatic, retracting needle that remains concealed before, during, and after injection, reducing visual and tactile needle cues.
  • Controlled insertion mechanism engineered to lower needle‑sensation forces and ensure precise dose delivery.
  • Integrated post‑use lockout that converts the device into a sharps‑safe container for effortless home disposal.
  • Compliance with FDA technical guidance for emergency‑use injectors and ISO‑aligned environmental qualification (temperature, drop, vibration, humidity, altitude).
  • API‑agnostic, partner‑ready platform supporting both subcutaneous and intramuscular formulations using existing FDA data pathways (505(b)(2), 351(k)).
  • Scalable manufacturing roadmap with DSCSA‑ready serialization and surge‑capacity automation for large‑volume retail and specialty launches.
  • Embedded data capture for dose confirmation and optional connectivity to digital health ecosystems.
This profile is AI-generated and may contain inaccuracies.